Abstract

In 2013, the CJEU ruled on the ‘Lyocentre’ case touching upon an important and contemporary issue in the EU Medical Device regime – the classification issue between medical devices and medicinal products. This problem is connected with the internal market v. protection of health dilemma as well as the choice between minimum and maximum harmonization. The Commission aspires to solve the above dilemma by going towards maximum harmonization in this area in the form of a proposal for a new Regulation on medical devices. My hypothesis is that the new regulatory framework may be able to better balance these objectives and also deal with several problematic issues of the medical device regime. However, it is not likely to solve the problem of borderline products. In order to check that, I will explore harmonization and internal market law literature as well as the relevant case law. My argument is that because classification of borderline products is strongly related to technology and medical science, which are constantly changing, a strict and inflexible regulatory framework cannot abide by their fast pace. I conclude that this problem cannot be fully eliminated, but it can be improved through soft law instruments, as they can be easily adapted to change.

Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.